Online Submissions

Already have a Username/Password for Rational Pharmacotherapy in Cardiology?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required to submit items online and to check the status of current submissions.

Author Guidelines

Rules for publishing copyright materials in the journal "Rational Pharmacotherapy in Cardiology" 

These Rules for the publication of copyright materials in the journal "Rational Pharmacotherapy in Cardiology" are developed on the basis of the requirements of the Civil Code of the Russian Federation (part 4) of 18.12.2006, No. 230, the Law of the Russian Federation "On Copyright and Related Rights" of 09.07.1993, No. 5351-1 as amended on July 19, 1995 and July 20, 2004, the Law of the Russian Federation "On the Mass Media" of 27.12.1991, No. 2124-I with subsequent amendments and regulate the relationship between the publishing house "Capital Publishing Company" represented by the editorial board of the journal "Rational Pharmacotherapy in Cardiology", hereinafter referred to as the "Editorial Board", and by the author who submitted their article for publication in the journal, hereinafter referred to as the "Author".

The scientific and practical peer-reviewed medical journal "Rational Pharmacotherapy in Cardiology" is included in the list of journals published with the support of the Russian Society of Cardiology and the National Medical Research Center for Therapy and Preventive Medicine.

The journal Rational Pharmacotherapy in Cardiology publishes peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, experimental studies of clinical relevance, review articles on current issues of cardiology (systematic reviews and meta-analyzes), expert discussions, descriptions of case studies, editorials, letters to the editor, guidelines and consensus documents.

Criteria for articles sent for publication: relevance, novelty of the presented material, theoretical/applied value.

The main directions in which materials are accepted for publication in the journal (Pharmacology (medical), Cardiology and cardiovascular medicine):

Aspects of cardiovascular disease:

• Pharmacotherapy
• Epidemiology
• Risk factors
• Genetic aspects
• Comorbid conditions
• Food
• Alcohol
• Smoking
• Psychosocial aspects
• Biomarkers
• Risk assessment and screening
• Clinical and instrumental diagnostics
• Clinical trials (phases 2, 3 and 4)
• Age aspects
• Treatment adherence
• Telemedicine
• Rehabilitation programs
• Preventive programs
• Sports cardiology
• Environmental aspects
• Socio-economic aspects

Traditionally, there are 6 issues that get published a year (every 2 months); and up to 8 issues per year.

The title of the journal in English:

Rational Pharmacotherapy in Cardiology, abbreviated as Ration Pharmacother Cardiol.

1. Submission Rules/Publishing Policy

1.1. Articles for publication in the journal are accepted on the official website of the journal - https://www.rpcardio.com. The editors can assist the authors and answer any questions that they may have. Contact information of the editors: otsec@sticom.ru.

1.2. Manuscripts are accepted for consideration only on the condition that they have not been submitted to other publications, have not been posted on the Internet and have not been published earlier.

1.3. The author, by sending the manuscript to the Editors, authorizes the Editors to publish it in the journal. When using the manuscript, the editors have the right to supply it with any illustrated or textual material, including ones of advertising nature, and allow third parties to do so.

1.4. The author, sending the manuscript to the Editorial Board, agrees that the Editorial Board will transfer non-exclusive property rights to use the manuscript (material transferred to the editorial office of the journal), including protected objects of copyright as photographs of the author, drawings, diagrams, tables, etc.; as well as its full or partial reproduction in print and on the Internet; for distribution; for translation of the manuscript (materials) into any languages ​​of the world; export and import of copies of the journal with the author's manuscript for the purpose of its full or partial distribution; for processing; for bringing up to the attention of the public.

1.5. The Author transfers The Rights, specified in paragraphs 1.3. and 1.4., to the Editors without limitation of their validity period and on the territory of all countries of the world without limitation, as well as on the territory of the Russian Federation.

1.6. The author guarantees that they have exclusive rights to use the material transferred to the Editorial Board. In case of violation of this guarantee and presentation, in this regard, claims to the Editorial Office, the Author, independently and at their own expense, undertakes to settle all claims. The editors are not liable to third parties for violation of the guarantees given by the Author.

1.7. The Author retains the right to use the published material, its fragments and parts for personal, including scientific, teaching purposes, as well as to publish fragments in other publications with a link to the main publication.

1.8. The rights to the manuscript are considered transferred by the Author of the Editorial Board from the moment of submitting for printing the issue of the journal in which the above manuscript is published.

1.9. Reprinting of materials published in the journal by other individuals and legal entities is possible only with the obligatory indication of the journal number (year of publication) in which the material was published.

1.10. The editors send the materials of the manuscript to experts on the topic discussed in it for an independent examination (review). Manuscript reviewing involves the principle of “double blind reviewing” - the Authors do not know who the reviewers are, and the reviewers do not know who the authors are, including their place of work or institution(s) where the manuscript comes from. The conclusion and recommendations of the reviewers can be sent to the Author(s) for making appropriate corrections. In case of untimely response from the Author(s) to the editorial request (1 month), the editorial board may refuse to publish the manuscript. Scientific editing, reduction and correction of the manuscript, changes in the design of graphs, figures and tables are aimed at bringing the material in accordance with the standards of the journal. The meaning of the information provided is not subject to change.

1.11. The editors are not responsible for the accuracy of the information presented in the manuscript by the Author(s).

1.12. The publication of materials in the journal is carried out in accordance with international and Russian standards of editorial ethics:

• "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication",
• Requirements of the International Committee of Medical Journal Editors (ICMJE) - http://www.icmje.org (published in issues 1-2 in 2010 and available on the journal's website)
• Committee on Publication Ethics (COPE) recommendations http://www.publicationethics.org.uk;
• Civil Code of the Russian Federation (Chapter 70, "Copyright"; http://www.consultant.ru/document/cons_doc_LAW_64629/0b318126c43879a845405f1fb1f4342f473a1eda/).
• Clinical trials must comply with CONSORT standards (http://www.consort-statement.org; published in issues 4-6 in 2010 and issue 1 in 2011 and are available on the journal's website), observational studies - STROBE standards (http://www.strobe-statement.org), systematic reviews and meta-analyzes - to the PRISMA standards (http://www.prisma-statement.org).

1.13. Articles sent with violation of the design rules are not accepted for consideration by the Editors of the journal.

2. The procedure for submitting materials to the journal

Submission of materials for publication is carried out via the website – https://www.rpcardio.com/jour/author/submit/1

Any of the authors can submit an article to the journal. This is usually done by the author responsible for correspondence with the editors (when submitting a manuscript through the site, one can choose to send notifications to all authors).

To submit a manuscript to the journal, the author must register on the website and follow the link “Submit an article".

Required documents when submitting a manuscript are: a direction letter, an information file, the material itself (article or other materials).

The absence of a direction letter, information file or their improper design is the basis for refusal to accept materials for consideration.

In the process of submitting a manuscript, you must follow the step-by-step instructions on the site.

All authors and all necessary information (places of work, eLibrary SPIN and ORCID - of all authors) are indicated in the form when submitting an article.

All information that is entered in the "article metadata" section must exactly match the data specified in the text of the article!

After the completion of the submission procedure, a notification about the receipt of the article by the Editors will be sent to the e-mail address indicated by the authors when submitting the manuscript (the absence of a letter is evidence that the manuscript was not received by the Editors). The author can contact the Editorial office, as well as track the stage of processing of his manuscript through their personal account on the journal's website.

All submitted articles are checked for plagiarism. The work may be rejected if it does not pass the anti-plagiarism check (the percentage of originality must be at least 70%).

2.1. Direction letter

The direction letter must be written in accordance with the template provided on the website.

The Directing Letter indicates the title of the article, its authors, and information that:

1) The manuscript is not under consideration in another publication;

2) Has not been published earlier;

3) Contains full disclosure of a conflict of interest;

4) All authors meet the criteria for authorship, have read and approved it;

5) The author(s) are responsible for the accuracy of the materials presented in the manuscript.

The Direction Letter should include the contact information of the author responsible for the correspondence.

If the manuscript is part of a dissertation work, then it is necessary to indicate the estimated terms of defense.

The Direction letter must be signed by all authors of the article.

It should be scanned and the file should be posted on the website along with the posted article.

Note: in a severe epidemiological situation, it is allowed that only one author is to sign the letter, i.e. in this case, it is necessary to attach to the Direction Letter the scanned consent of each author to submit the article for publication (the template is presented on the website).

Lack of a Direction letter or an incomplete text of the letter (not containing the above points) is the basis for refusal to accept the manuscript for consideration.

2.2. Information file

An Information File must be prepared and submitted electronically, which includes: title page, conflict of interest and work funding information, ethical compliance information, information on overlapping publications, copyright information, and word counts, tables and figures.

The info file template is available on the website.

2.2.1. Title page

The title page includes the title of the paper and information about the author(s) in Russian and English.

Paper title should be written in bold, should not contain hyphens, abbreviations (except for research names), trade names of medicinal products. The title should be short (no more than 20 words) and should reflect the main idea or results of the work.

Information about authors and institutions. Includes the title of the article in Russian and English, the surnames and initials of the authors (Ivanov I.I.), their affiliation (institutional affiliation), the full name of the institution(s) from which the manuscript came, indicating the city and country. Affiliation is indicated by Arabic numerals after each author and before the names of institutions. The surnames and initials of the authors should also be presented in the English-language spelling accepted by the authors. The name(s) of the institution(s), including city and country, must be in the officially accepted English language.

Example:

Comorbid conditions and percutaneous coronary intervention in elderly patients with acute coronary syndrome

Gilyarov M.Yu.^1,2,3, Konstantinova E.V. ^{1,2 *,} Atabegashvili M.R. ¹, Solntseva T.D.⁴

¹City Clinical N.I. Pirogov Hospital No. 1, Moscow, Russia

²Russian National N.I. Pirogov Research Medical University, Moscow, Russia

³First Moscow State Medical Sechenov University (Sechenov University), Moscow, Russia

⁴National Medical Research Center of Cardiology, Moscow, Russia

2.2.2. Information about authors include their last names, first names and patronymics, eLibrary SPIN and ORCID.

Example:

Ivan I. Ivanov

eLibrary SPIN 1234-1234, ORCID 1234-1234-1234-1234

2.2.3. Short title of the article (no more than 45 characters) to be placed on headers and footers.

2.2.4. Under the heading "Corresponding author" the author should provide the full name, full postal address, e-mail, and phone number of the author for future correspondence.

2.2.5. Conflict of interest information.

This section should contain information on the possible relationship of each of the authors with industrial and financial organizations, which may cause a conflict of interest in connection with the material presented in the manuscript.

A Conflict of Interest Statement is generated by completing a form recommended by the ICMJE for peer-reviewed scientific journals (www.icmje.org/conflicts-of-interest). Each author must fill a separate form responsibly, thoroughly and completely. The form contains 5 sections (Personal information; Information about the submitted paper; Information about financial activities not related to the submitted paper; Intellectual property; Other relationships).

If there is no conflict of interest, then one should write: "the author(s) declares that there are no conflict of interest."

Information concerning a conflict of interest should also be reflected at the end of the text of the article (Relationships and Activities).

For more information on Conflict of Interest and the ICMJE Form, please visit: https://www.rpcardio.com/jour/manager/files/2/2/coi_disclosure1.pdf

2.2.6. Funding information

In this section, it is necessary to reflect the sources of funding for the paper. As a source of funding, can be indicated: grants from a third-party organization (government agencies, foundations, commercial sponsors, academic institutions, etc.); individual payment (money paid for your services – consulting, lectures, reports, expert assessments, contract work, etc.); non-financial support (medical supplies/equipment provided, travel arrangements, writing assistance, administrative support, etc.). The funding information should contain a full description of the role of the funding source in the execution of the work (design, information gathering, analysis, data interpretation, etc.).

If during the work no grants or any other external sources of funding were used, it is necessary to indicate the institution in which the work was performed as a source of funding.

2.2.7. Information and compliance with ethical standards.

It is necessary to reflect in the publication:

(1) The principles according to which the study was carried out (for example, the principles of the Declaration of Helsinki);

(2) Whether the study was approved by an independent Ethics Committee (in accordance with the purpose and design of the study by the decision of which ethical committee the study was approved);

(3) Whether patients signed informed consent to participate in the study;

(4) Information on the registration and placement of data on the ongoing research in any public register of clinical trials. The term "clinical research" refers to any research project that involves people (or groups of subjects) with or without a comparative control group, and examines the interaction between interventions to improve health or the results obtained. The World Health Organization offers the following platform for this purpose: International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/network/primary/en/index.html).

Information regarding compliance with ethical standards (permits, questionnaires, etc.) may be requested from authors additionally when preparing a paper for publication.

2.2.8. Authors' Contributions

2.2.9. Overlapping post information (if available).

If articles or other materials have been previously published by the authors on the topic of the work, one must indicate them.

2.2.10. Copyright Information. The use in the article of any material (table, figure) marked with a copyright icon must be confirmed by special permission from the copyright holder.

2.2.11. The number of words, tables and figures.

The number of words in the article and other materials is calculated without taking into account the title, authors, their place of work, summary and bibliography.

The lack of an information file or an incomplete text (not containing the above points) is the basis for refusal to accept the manuscript for consideration.

2.3. Main manuscript file

2.3.1. General guidelines for manuscript submission

2.3.1.1. The article should be typed in Times New Roman, 12, double-spaced; width of margins 2 cm on the left, right, top and bottom (1 page is 1800 characters, including spaces). Page numbering should start with a title page.

2.3.1.2. To ensure “blind reviewing”, the main file of the manuscript sent to the reviewers should be organized as follows: 1) the title of the article; 2) summary and keywords (4-8 keywords or two-syllable phrases); 3) a list of abbreviations; 4) the text of the article; 5) acknowledgments (if available); 6) conflict of interest (relationships and activities); 7) financing; 8) a list of references indicating DOI sources; 9) figures, tables, diagrams, photocopies with titles and legends (if necessary) – on separate pages of the same document in the order of presentation in the manuscript. Samples of structuring manuscripts can be found on the website (Original article, Literature review).

2.3.1.3. In the title of the work, it is necessary to indicate the international non-proprietary name of drugs. Exceptions are cases where the use of trade names is substantively justified (for example, when the results of studies of bio- or therapeutic equivalence of drugs are published). The trade name can be used in the text, but no more than 1 time per standard page (1800 characters with spaces), and a conflict of interest must reflected this fact.

2.3.1.4. The length and structure of the abstract depend on the type of the manuscript (p. 3). In addition to the text of the summary in Russian, one must attach its full translation into English.

At the end of the summary, 4-8 keywords or two-syllable phrases are necessary to be included.

2.3.1.5. To save space in the journal, up to 10 abbreviations of common terms (for example, ECG, PCI, CABG) or names (GUSTO, SOLVD, TIMI) can be used throughout the manuscript. You can use abbreviations for terms that appear in the text 3 or more times. On a separate page following the structured abstract, there is a list of selected abbreviations and their definitions (for example, CABG - coronary artery bypass grafting).The first mention of an abbreviation is always accompanied by the full spelling of the abbreviated concept with an indication of the abbreviation in brackets. Special terms should be given in Russian translation and only words generally accepted in scientific literature should be used. It is strictly not recommended to use foreign words in the Russian version in the original transcription.

2.3.1.6. All units of measurement in the manuscript must be presented in the SI system. Abbreviations of words are not allowed, except for the generally accepted abbreviations of chemical and mathematical quantities and terms.

2.3.1.7. All published materials can be reviewed for the consistency and accuracy of statistical methods and statistical interpretation of the results. Materials must comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. N Engl J Med. 1997; 336 (4): 309-15. DOI:10.1056 / NEJM199701233360422.). In the preparation of the statistical part of the work, it is recommended to use special guidelines, for example, the European Journal of Cardiology: https://academic.oup.com/eurheartj/pages/Statistical_Guidelines. In the Methods section, there should be a subsection detailing the statistical methods, including the specific methods used to summarize the data; methods used to test hypotheses (if any), and the level of significance for testing hypotheses. When using more complex statistical methods (in addition to t-test, chi-square, simple linear regression), the statistical package used to process the results and its version number must be indicated.

2.3.1.8. The journal uses NLM (National Library of Medicine) citation style (reference in the text in Arabic numerals in square brackets, full bibliographic description of the source in the list of references in the order of mention in the text of the article):

Author AA, Author BB, Author CC, et al. Title of article. Title of Journal. 2021; 10 (2): 49-53.

2.3.1.9. The list of references should be typed in double spaced on a separate sheet of the manuscript, each source - on a new line under a serial number. The list of references should be compiled in the order of citation of the authors. One should use Index Medicus to find journal abbreviations.

2.3.1.10. All documents referred to in the text should be included in the bibliography. The authors are responsible for the correctness of the data in the list of references.

2.3.1.11. The list of references does not include references to dissertations and abstracts published more than two years ago, as well as materials that cannot be verified (materials from local conferences, etc.). One should indicate the relation of the material to the abstracts in brackets (abstract).

2.3.1.12. Transliteration (translation of the Cyrillic font into the Latin alphabet) of Russian-language sources using official encodings is required in the following order: the authors and the title of the journal are transliterated using encodings, and the title of the article is a semantic translation into English. If there is an original transliteration of the source, the latter is used. For transliteration, you should use online services (for example, http://translit.ru). Below are examples of transliteration of Russian-language (Cyrillic) sources into the Latin alphabet.

Russian-language source without original transliteration:

Скворцов В.В., Халилова У.А. Актуальные вопросы диагностики и лечения инфаркта миокарда. Поликлиника. 2016;2(1):66-70.

Transliteration and presentation of the source in the list of references:

Skvorcov VV, Halilova UA. Actual questions of diagnostics and treatment of myocardial infarction. Poliklinika. 2016; 2 (1): 66-70 (In Russ.) [Скворцов В.В., Халилова У.А. Актуальные вопросы диагностики и лечения инфаркта миокарда. Поликлиника. 2016;2(1):66-70].

Russian-language source with original transliteration:

Смирнова М.И., Оганов Р.Г., Горбунов В.М. и др. Скрытая неэффективность лечения артериальной гипертонии: частота и предикторы. Кардиоваскулярная Терапия и Профилактика. 2011;10(6):11-7].

Transliteration and presentation of the source in the list of references:

Smirnova MI, Oganov RG, Gorbunov VМ. The hidden ineffectiveness of treatment of arterial hypertension: frequency and predictors. Cardiovascular Therapy and Prevention. 2011;10(6):11-7 (In Russ.) [Смирнова М.И., Оганов Р.Г., Горбунов В.М. и др. Скрытая неэффективность лечения артериальной гипертонии: частота и предикторы. Кардиоваскулярная Терапия и Профилактика. 2011;10(6):11-7].

2.3.1.13. The literature list should follow the format recommended by the National Information Standards Organization (NISO), adopted by the National Library of Medicine (NLM) for its databases (Library's MEDLINE / PubMed database) and updated in 2009. Authors should consult the NLM website for recommended formats for a variety of link types: http://www.nlm.nih.gov/citingmedicine. Below are examples of link formatting in accordance with the NLM guidelines.

Periodicals

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulations and Risk factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285 (18): 2370-5.

Russian-language sources with transliteration:

• Baevskiy RM, Ivanov GG, Chireykin LV, et al. Analysis of heart rate variability using different ECG systems (guidelines). Vestnik Aritmologii. 2002;24:65-86 (In Russ.) [Баевский Р.М., Иванов Г.Г., Чирейкин Л.В. и др. Анализ вариабельности сердечного ритма при использовании различных электрокардиографических систем (методические рекомендации). Вестник Аритмологии. 2002;24:65-86].

The surnames of the authors are written first, followed by the initials. The names of foreign authors are given in the original transcription. Periodical titles may be abbreviated. Usually this form of writing is independently adopted by the publication; it can be found on the publisher's website or in the Index Medicus abbreviation list.

Please pay attention to the punctuation of the links. A full stop is not put between the name of the journal and the year of its issue; after the year of issue, a semicolon, volume (number), colon, pages follow without a space. There are no designations for "volume", "No.", "pages". References to Russian periodical literature sources often do not have a volume or continuous pagination throughout the year. In this case, the issue number should be indicated in brackets.

If there are more than 4 authors, you can specify the first 3 authors and write “et al.” or "and others." If there are 4 or less authors, all authors must be indicated.

Book

Russian-language sources with transliteration:

• Shlyakhto EV, Konradi AO, Tsyrlin VA. The autonomic nervous system and hypertension. SPb.: Meditsinskoe Izdatel'stvo; 2008 (In Russ.) [Шляхто Е.В., Конради А.О., Цырлин В.А. Вегетативная нервная система и артериальная гипертензия. СПб.: Медицинское издательство; 2008].

Chapters in a book

• Swanton RH, Banerjee S. Cardiac Failure. In: Swanton RH, Banerjee S, eds. Swanton's Cardiology: A concise guide to clinical practice. Sixth Edition. Oxford: Blackwell Publishing; 2008. pp. 255-309.

Russian-language sources with transliteration:

• Belenkov YuN. Cardiomyopathies. In.: Chazov EI, Belenkov YuN, eds. Rationale for drug therapy of cardiovascular diseases: A guide for medical practitioners. Moscow: Litterra Publishers; 2006. pp. 431-452 (In Russ.) [Беленков Ю.Н. Кардиомиопатии. В: Чазов Е.И., Беленков Ю.Н., редакторы. Рациональная фармакотерапия сердечно-сосудистых заболеваний: Руководство для практикующих врачей. М.: Литтерра; 2006. с. 431-452].

When referring to a chapter in a book, one should first indicate the authors of the corresponding chapter, then the title of the chapter. Next, one should indicate "In:", then the editors (titled authors) of the book, its title, edition number, publisher, city of issue, year and pages related to the corresponding chapter. Pay attention to punctuation. There are no quotes. In Russian sources, the cities of publication Moscow and St. Petersburg can be designated briefly by the letters M and SPb, respectively.

Patents

Russian-language sources with transliteration:

Eskov DN, Bonstedt BE, Koreshev SN, et al. Patent of Russia № 2000130511/28, 04.12.2000. Optoelectronic apparatus. Patent of Russia № 2122745.1998. Bulletin № 33 (In Russ.) [Еськов Д.Н., Бонштедт Б.Э., Корешев С.Н. и др. Патент РФ № 2000130511/28, 04.12.2000. Оптико-электронный аппарат. Патент России № 2122745. 1998. Бюллетень № 33].

Legislative acts

Russian-language sources with transliteration:

Federal Law “On the Circulation of Medicines” dated 12.04.2010 N 61-FZ. Available from: https://rg.ru/2010/04/14/lekarstva-dok.html (In Russ.) [Федеральный закон «Об обращении лекарственных средств» от 12.04.2010 № 61-ФЗ. Доступен на: https://rg.ru/2010/04/14/lekarstva-dok.html]  

Internet resources

Websites should be listed in the bibliography, but not in the text (in the text it is possible to use the names of the main pages of Internet resources, for example www.grls.rosminzdrav.ru; www.ncbi.nlm.nih.gov; www.who .int, etc.). Links to documents (pages) from websites should only be used when the original printed text is not available. Links should be formatted as follows:

WHO. Severe Acute Respiratory Syndrome (SARS) [cited by May 10, 2021]. Available from: www.who.int/csr/sars/en/index.html.

2.3.1.14. After the bibliographic reference, one should indicate the digital identifier of the source posted on the Internet – DOI (Digital Object Identifier, digital object identifier) ​​- if available. The DOI can be found in the article itself, at http://search.crossref.org, on the article page in PubMed. For example:

Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379(9813):322-34. DOI:10.1016/S0140-6736 (11) 61294-4.

2.3.1.15. Graphs, diagrams and pictures are accepted in electronic form in formats that can be edited in "MS Excel", "Adobe Illustrator", "Corel Draw" or "MS PowerPoint". Graphs, diagrams and figures should be placed on separate pages of the manuscript, numbered in the order of mention in the text, have a title and, if necessary, notes. They should not repeat the content of the tables. There is no need to duplicate information from tables and figures in the text of the article (numerical data from tables and figures should not be repeated, but described in the text of the article). The axes of the graphs must have names and dimensions. The graph should be provided with a legend (designation of lines and fills). When comparing charts, the statistical significance of the differences should be indicated. It is not allowed to use 3D models for the histogram. Places for the desired placement of graphs, diagrams and figures should be indicated in the text of the article. All graphic material is published in Russian and English - names, all inscriptions on figures, graphs and diagrams should also be translated into English.

2.3.1.16. Pictures should be of good quality, suitable for printing (when enlarging a picture, there should be no blurring of the image). These are attached to the article in separate files. Photos must be in electronic form with a resolution of at least 300 dpi (dots per inch). The cropping point in the photomicrograph should show only the main margins. It is necessary to indicate the features with arrows. All symbols, arrows and lettering in halftone illustrations must contrast with the background.

2.3.1.17. Captions on figures and photographs must be of sufficient size to be legible when compressed for publication. The optimal size is 12 points.

2.3.1.18. All abbreviations used must be identified either after their first mention in the legend, or in alphabetical order at the end of each legend. All symbols used (arrows, circles, etc.) must be explained.

2.3.1.19. Tables must be double-spaced, numbered corresponding to the order in which they appear in the text, and have a title. Tables should be constructed concisely, clearly, have column and row headings strictly corresponding to their content. The data presented in the tables should not be duplicated in the text or figures. The tables should clearly indicate the dimension of the indicators and the form of data presentation (M ± SD; Me [25%; 75%], etc.). All numbers, totals and percentages in the tables must be carefully verified, and also correspond to their mention in the text. If necessary, explanatory notes are provided below the table. The information contained in the table (title, content, note) must be translated into English.

2.3.1.20. Abbreviations should be listed alphabetically in a footnote below the table. Footnote symbols must be listed in the following order: *, †, ‡, §, | |, ¶, #, **, † †, etc.

2.3.1.21. When using figures, tables, diagrams, photocopies presented in previously published materials, links to the authors and sources of publication, as well as the permission of the copyright holder for their use, are required. It should be remembered that although the clinical guidelines of the professional communities are generally available, their content may only be published for personal and educational use. No part of the clinical guidelines may be translated or reproduced in any form without the written permission of the publisher. You can get permission after submitting a written request to the relevant publisher (depending on the source, it can be paid or free). This applies to all previously published material.

When using images from stock sources, you need to be aware of the type of licenses (paid/free) for this material. All the necessary information (type of license, additional rules for the use of images) is indicated on the stock website.

It’s possible to place text, for example, attachments with a list of studies included in the systematic review as additional material available online on the journal's website.

3. Types of manuscripts accepted by the journal

3.1. Original article. The volume of the original article, taking into account the list of references, graphs, figures and tables, should not exceed 15 standard typewritten pages (1 page 1800 characters, including spaces). The number of sources of literature should not exceed 40. Manuscripts based on the description of original research should contain the following sections: 1) Title; 2) Structured abstract (not less than 300 and not more than 400 words: Purpose, Material and methods, Results, Conclusion) with keywords; 3) Introduction (brief, revealing the relevance of the problem under study and the objectives of the study); 4) Material and research methods; 5) Research results; 6) Discussion; 7) Limitations of the study; 8) Conclusion; 9) Conflict of interest (relationships and activities); 10) Financing; 11) Acknowledgments (if available); 12) References indicating DOI sources; 13) Figures and tables.

The presentation should be clear, concise and free of repetitions. The section "Material and Methods" should contain information about the study design (criteria for inclusion and exclusion of patients, main and additional assessed parameters/endpoints, study methods, equipment used with an indication of the manufacturer and country, international non-proprietary names of drugs used with an indication of the dose and route introduction, methods and principles of distribution into groups, methods of statistical analysis), the conclusion of the ethical committee, the signing of voluntary informed consent by the study participants. The research methods used must ensure that the results can be reproduced.

The results should be presented in short descriptions in a logical sequence with indications to graphs, tables and figures, should clearly reflect the research data without discussion and references to literary sources.

The discussion presents the identified new and important aspects of the study, an explanation of the results obtained, a comparison of one’s own results with the data of other researchers, the need for further research. The section should end with a statement of the strengths and weaknesses of the study carried out in comparison with existing analogues, and the limitations of the study. One should avoid repeating information from the "Introduction" section and listing details from the "Results" section.

In the conclusion, one should briefly and concisely present the results of the work and the authors' judgment on the significance of the data obtained regarding the pathogenesis, diagnosis, treatment, prevention, and the prospects for their use.

Articles based on the description of the results of uncontrolled studies (with the absence of a control group) will be accepted for publication in the "Clinical experience" section only on condition that the uncontrolled design (as a study limitation) is reflected in the "Material and Methods" and "Discussion" sections. In addition, the "Conclusion" section should not exaggerate the significance of the results obtained.

3.2. Literature review. The volume of the review article, taking into account the list of references, graphs, figures and tables, should not exceed 25 standard typewritten pages (1 page 1800 characters, including spaces). The number of literature sources should not exceed 80. Review articles should contain the following sections: 1) Title; 2) Unstructured or structured abstract (no less than 200 and no more than 300 words) with keywords; 3) Introduction (brief, revealing the relevance of the problem under study and the objectives of this review); 4) Subsections reflecting the main directions of the review; 5) Conclusion; 6) Conflict of interest (relationships and activities); 7) Financing; 8) Acknowledgments (if available); 9) References indicating DOI sources; 10) Figures and tables.

Review articles refer to secondary scientific literature devoted to the analysis, synthesis and assessment of information originally presented in the primary scientific literature on any general topic (previously published scientific literary texts presenting the results of original research, preliminary reports and other materials that meet the criteria of primary scientific publications). Review articles, which are based on analytical and synthetic interpretation of the results of original research, should serve as a basis for the emergence of new ideas, hypotheses, theories and paradigms.

The literature review should have a clear scientific purpose, reflect recent advances in relevant topics, critically consider the status of literature sources, and identify gaps in knowledge on topics and directions for future research. Systematic reviews and meta-analyzes are preferred.

In a descriptive review, the authors should indicate the novelty and advantages of this review in comparison with already published review papers on this topic. The review should reflect the methodology for its preparation (platform/websites used, the number of studies reviewed, keywords used for selection), a critical analysis of the submitted works (including an assessment of the adequacy of statistical methods), and a well-founded personal opinion on the topic under discussion, as well as a conclusion disclosing the existing gaps on this topic and possible directions for scientific research.

When using borrowed tabular and/or graphic material, permission of the copyright holder is required to reproduce them.

The literature used to prepare the review should contain mainly sources not older than 5 years, including domestic works, which helps to confirm the relevance and scientific novelty of the topic under study.

3.3. Clinical case. The volume of the description of a clinical case (notes from practice) is no more than 10 standard typewritten pages (1 page 1800 characters, including spaces). The number of literature sources should not exceed 15.

Descriptions of clinical cases should contain the following sections: 1) Title; 2) Abstract (descriptive; no less than 100 and no more than 150 words) with keywords; 3) Introduction (brief, revealing the relevance of the problem under study; reflection of the practical/scientific value of the case); 4) Description of the clinical case; 5) Discussion; 6) Patient's point of view (optional section); 7) Conclusion; 8) Conflict of interest (relationships and activities); 9) Financing; 9) Acknowledgments (if available); 10) References indicating DOI sources; 11) Figures and tables.

A descriptive summary is written without headings, contains a logical summation of the research and a brief description of its results.

The case report has a relatively weak quality of evidence and measurement limitations. The advantage of this format is clarity, accessibility and ease of understanding of the presented scientific information for medical specialists. The study of an individual case is carried out in real conditions of medical practice and is devoid of restrictions associated with the recruitment of the required number of subjects, financial costs and mandatory regulation of clinical trials.

Case reports can highlight: unusual or rare drug side effects or drug interactions; previously unknown or unusual manifestation of the disease, a variant of its course; peculiarities of diagnosis or treatment of a new disease; unique therapeutic approaches; unanticipated relationships between diseases or symptoms; an unexpected clinical event that occurred during the observation or treatment of a patient; a clinical discovery that expands the understanding of the pathogenesis of the disease or the formation of a side effect.

The message must include a description of the ethical aspect, the presence of the patient's informed consent for publication. When describing a case with a fatal outcome, informed consent must be obtained from his closest relative or, if there is none, from the ethics committee. Patient photographs must be posted anonymously.

The section "Description of the clinical case" should contain all the necessary information about the patient. The description should include the main complaints reported by the patient; a description of the symptoms and manifestations of the disease; the results of diagnostic studies and procedures with their informative visualization, which allows one to visually present the features and uniqueness of a given case; preliminary diagnosis and, if necessary, its change with indication of the reasons; pharmacotherapeutic, surgical treatment and other interventions; outcome, duration of treatment/observation (in a hospital, clinic, etc.), medical rehabilitation and other necessary information.

Discussion is a mandatory and most important section, containing additional information and an explanation of the uniqueness of this case, the reasons for choosing the management tactics (diagnostic procedures and treatment). It is recommended to describe the algorithm of differential diagnostic search, the process of forming a clinical diagnosis, diagnostic problems and their discussion, prognosis, and applicability in clinical practice. The discussion is encouraged to reflect the strengths and limitations of the case. One’s opinion about the case must be correlated with a discussion of the medical literature data.

In the Conclusion, the authors indicate the novelty of the presented case, the main conclusions following from this description, the practical and scientific importance.

3.4. Editorial. The volume is no more than 6 standard typewritten pages (1 page 1800 characters, including spaces). It does not require an abstract, and may include 1 figure and 1 table. The number of literature sources should not exceed 10. It may be written by the editor-in-chief, executive editor of the issue, guest editor/expert and reflect their opinion on the current issue of the journal or major research, or publicly significant event in the field of pharmacotherapy of cardiovascular diseases. The author's judgment should be based on evidence-based medicine.

3.5. Letter to the editor. The letter to the editor should reflect comments on published articles in previous issues of the journal. The volume is no more than 3 standard typewritten pages (1 page 1800 characters, including spaces). The number of literature sources should not exceed 5. The author's judgments should be based on evidence-based medicine. If the letter to the editor requires a response from the authors of the article, then their response can be published alongside with the Letter to the editor.

3.6. Clinical guidelines and consensus documents. Methodological recommendations and consensus documents from professional communities and expert groups in relevant areas are accepted for publication. These documents summarize the current state of the problem and the ways to solve it (in the opinion of the professional community or a group of experts). The volume is no more than 30 standard typewritten pages (1 page 1800 characters, including spaces). The number of literature sources should not exceed 60. A short, unstructured summary (200-250 words).

4. Ethical aspects

4.1. Research should be conducted in accordance with the guidelines of the Law "On Circulation of Medicines" of 12.04.2010, No. 61 (if these studies were carried out in whole or in part on the territory of the Russian Federation) and/or the principles of Good Clinical Practice. Participants in the study must be familiar with the goals and main provisions of the study, after which they must sign a written informed consent to participate in it. Authors should provide details of the above procedure when describing the study protocol in the Material and Methods section, and indicate that the Ethics Committee approved the study protocol. If the examination procedure includes X-ray methods, it is advisable to provide their description and exposure doses in the Material and Methods section.

4.2. Patients have the right to privacy and protection (confidentiality) of personal information. Therefore, information including images, names, initials of patients or numbers of medical records should not be presented in research materials. If this information is relevant for scientific purposes, it is necessary to obtain written informed consent from the patient (or parent, guardian, next of kin, where applicable) for its publication in print and electronic form. If necessary, written consent must be provided to the editor upon request.

4.3. Research on animals must comply with the "Good Laboratory Practice", approved by the Order of the Ministry of Health and the SR of 23.08.2010 N 708n, and the "International Recommendations for Biomedical Research Using Animals" adopted by the International Council of Medical Scientific Societies (CIOMS) in 1985.

Information on ethical aspects should be reflected in the Material and Methods section. For example:

The study was carried out in accordance with Good Clinical Practice and the principles of the Declaration of Helsinki. The study protocol was approved by the local (interuniversity) ethical committee (protocol No. 1 dated 01/01/2021). All study participants signed voluntary informed consent prior to inclusion in the study.

When preparing a paper for publication, the authors may additionally be required to provide additional information (permits, questionnaires, etc.).

5. Authorship

5.1. Each author must make a meaningful contribution to the work submitted for publication.

Authors must meet all four criteria for authorship formulated in the ICMJE (International Committee of Medical Journal Editors) guidelines:

1) Making a significant contribution to the development of the concept and design of the work or the analysis and interpretation of data;

2) Writing an article or critical revision of its intellectual content;

3) Approval of the latest version of the article before going to press;

4) Agreement to be responsible for all aspects of the work.

If persons who do not meet the criteria for authorship contributed to the writing of the article or the conduct of the work, they can be indicated at the end of the text of the article in the "Acknowledgments" section. Acknowledgments section should contain no more than 100 words. For example:

Acknowledgments:

The authors are grateful to N.V. Aleksandrov for scientific advice during the preparation of the manuscript and to the chief physician of polyclinic No. 001 D.S. Sidorov for administrative support during the study.

5.2. If the author's list of a manuscript contains more than 4 authors, it is necessary to indicate the contribution to this manuscript of each author in a covering letter. If authorship is attributed to a group of authors, all members of the group must meet all criteria and requirements for authors. To save space, the members of the research team can be listed in a separate list at the end of the article. Authors' participation in the work presented in the manuscript may be as follows: 1) Concept and design development or data analysis and interpretation; 2) Substantiating the manuscript or reviewing critical intellectual content; 3) Final approval for the submission of the manuscript. Participation in data collection alone does not justify authorship; in this regard, a notice can be made in the Acknowledgments section.

6. Conflict of interest/funding

6.1. It is necessary for the authors to disclose (in the form of a direction letter and on the title page) possible relationships with industrial and financial organizations that could lead to a conflict of interest in connection with the material presented in the article. A conflict of interest exists when a publication may affect the author's financial or personal relationships with other people or organizations. In the absence of these relations and activities, the absence of a conflict of interest is implied.

A Conflict of Interest Statement is generated by completing a form recommended by the ICMJE for peer-reviewed scientific journals (www.icmje.org/ conflicts-of-interest /).

6.2. It is necessary to indicate the availability and source of research funding (grant, support of non-profit / commercial organizations, etc.).In the absence of support from public, non-profit and commercial organizations funding is carried out by the organization in which the work is done. For example:

Financing. The study was supported by the National Medical Research Center for Therapy and Preventive Medicine.

Financing. The research was carried out with the support of the pharmaceutical company Almanakh.

Financing. This work was financially supported by the Russian Science Foundation (Grant No. XX-XX-XX-XXX).

Copyright Notice

Authors who publish with this journal agree to the following terms:

1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Data Privacy Statement

Specified when registering the names and addresses will be used solely for technical purposes of a contact with the Author or reviewers (editors) when preparing the article for publication. Private data will not be shared with other individuals and organizations.